← Human Trials & Peer-Reviewed Studies
Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension
Plain-language guide to PMID 8340158 (1993): double-blind randomized controlled trial study of BNP (Nesiritide) and Angiotensin II.
Key Facts
- PMID
- 8340158
- Journal
- Hypertension (Dallas, Tex. : 1979)
- Year
- 1993
- Study type
- Randomized Controlled Trial
- Authors
- Richards AM et al. (5 authors)
- DOI
- 10.1161/01.hyp.22.2.231
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at BNP (Nesiritide) and Angiotensin II.
In contrast to the wealth of information available concerning the response of plasma atrial natriuretic peptide to changes in pressure and volume status and to inhibition of endopeptidase 24.11, very little is known of possible concomitant effects on brain natriuretic peptide.
The effects of change in posture, pressor infusions of angiotensin II, or inhibition of endopeptidase 24.11 were documented in two groups of patients with essential hypertension receiving one of two orally active inhibitors (SCH 42495 or UK 79300) in double-blind, placebo-controlled, random-order crossover studies.
Who Took Part
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, men only.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.
Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received BNP (Nesiritide).
A placebo (an inactive look-alike) gave the BNP (Nesiritide) group a baseline to be compared against.
In the crossover set-up each of the participants took both BNP (Nesiritide) and the comparison in turn, acting as their own control.
What Was Measured
Topics PubMed links to this paper include Angiotensin II, Atrial Natriuretic Factor, Hypertension, Indans, Methionine, Natriuretic Peptide, Brain and Neprilysin.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide) and Angiotensin II.
The publication is from 1993 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.
More context: the BNP (Nesiritide) compound page and the Angiotensin II compound page, all human trials.
Our Notes on the Compounds
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.